| Drug Name: | Methimazole (60-56-0) |
|---|---|
| PubChem ID: | 1349907 |
| SMILES: | CN1C=CNC1=S |
| InchiKey: | PMRYVIKBURPHAH-UHFFFAOYSA-N |
| Therapeutic Category: | Antithyroid Agents, Hormone Antagonists, Hormones |
| Molecular Weight (dalton) | : | 114.173 |
| LogP | : | 1.08269 |
| Ring Count | : | 1 |
| Hydrogen Bond Acceptor Count | : | 2 |
| Hydrogen Bond Donor Count | : | 1 |
| Total Polar Surface Area | : | 20.72 |
This panel provides information on interacting drugs and their ADRs along with references
| Interacting drug | Toxicity | Interaction Type | Mechanism | Reference |
|---|
This panel provides drug-protein interaction and their ADRs along with references
| Toxicity | Interacting Protein | Mechanism | Reference |
|---|---|---|---|
| Autoimmune Syndrome | HLA class II histocompatibility antigen DRB1-1 (P04229) | Allele specificity of structural requirement for peptides bound to HLA-DRB1 0405 and -DRB1 0406 complexes,which implicates for the HLA-associateb susceptibility to methimazole-induced insulin autoimmune syndrome [ ADR Type 5 ] | Naturally processed peptides from two disease-resistance-associated HLA-DR13 alleles show related sequence motifs and the effects of the dimorphism at position 86 of the HLA |
| Insulin Autoimmune Syndrome | HLA class II histocompatibility antigen DRB1-1 (P04229) | Allele specificity of structural requirement for peptides bound to HLA-DRB1 0405 and -DRB1 | Allele specificity of structural requirement for peptides bound to HLA-DRB1 0405 and -DRB10406 complexes: implication for the HLA-associated susceptibility to methimazole-induced |
This panel provides drug-food interactions and their ADRs along with references
| Food | Toxicity | Reference |
|---|
This panel provides information on metabolites and their ADRs along with references
| Metabolite | Toxicity | Place of Metabolism | Mechanism | Reference |
|---|
This panel provides information on drug category